USING IMAGING IN IMMUNO-ONCOLOGY TO IMPROVE AND ACCELERATE DRUG DEVELOPMENT

Immunotherapy (IOT) agents are increasingly being used in clinical trials to treat solid tumors due to their dramatic effects on tumor response. However, the assessment of tumor response is not always straightforward given IOTs unique mechanisms of action which include enhancing immune cell infiltration of tumors, draining lymph node basins and inducing generalized systemic inflammatory changes. These inflammatory episodes can lead to radiographic pseudo-progression whereby there can be an initial worsening of radiographic lesions, often accompanied by the appearance of new lesions, followed by lesion improvement or resolution. As a result, the innate and adaptive immune system responses that immuno-therapy agents demonstrate requires unique approaches in the evaluation to reveal treatment response that can be substantially different from standard RECIST methodologies used for chemotherapeutic agents.

USING IMAGING IN IMMUNO-ONCOLOGY TO IMPROVE AND ACCELERATE DRUG DEVELOPMENT

Immunotherapy (IOT) agents are increasingly being used in clinical trials to treat solid tumors due to their dramatic effects on tumor response. However, the assessment of tumor response is not always straightforward given IOTs unique mechanisms of action which include enhancing immune cell infiltration of tumors, draining lymph node basins and inducing generalized systemic inflammatory changes. These inflammatory episodes can lead to radiographic pseudo-progression whereby there can be an initial worsening of radiographic lesions, often accompanied by the appearance of new lesions, followed by lesion improvement or resolution. As a result, the innate and adaptive immune system responses that immuno-therapy agents demonstrate requires unique approaches in the evaluation to reveal treatment response that can be substantially different from standard RECIST methodologies used for chemotherapeutic agents.

PDF Download